AbbVie Inc. reported its first-quarter 2025 financial results with adjusted earnings per share (EPS) of $2.46, surpassing the consensus estimate of approximately $2.38. The company's net revenue reached $13.34 billion, exceeding expectations of around $12.92 billion. Key product revenues included Skyrizi at $3.43 billion, beating the estimated $3.2 billion, Rinvoq at $1.72 billion versus an estimate of $1.58 billion, and Humira at $1.12 billion, which fell short of the $1.32 billion estimate. On a GAAP basis, AbbVie reported diluted EPS of $0.72, a decline of 6.5%, while adjusted diluted EPS increased by 6.5%. The results included an unfavorable impact of $0.13 per share related to acquired in-process research and development (IPR&D) and milestone expenses. For the full year 2025, AbbVie projects adjusted EPS in the range of $12.09 to $12.29, an upward revision from the prior guidance of $11.99 to $12.19. The company noted that its forecast does not reflect any potential trade policy shifts and is based on existing conditions.